Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:CING NASDAQ:MRKR NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$7.31+4.6%$10.16$6.20▼$75.00$13.60M0.73186,387 shs43,360 shsCINGCingulate$4.72+4.4%$4.15$1.80▼$20.83$20.06M-0.791.10 million shs97,950 shsMRKRMarker Therapeutics$1.59+1.3%$1.43$0.95▼$5.99$17.99M1.43118,658 shs57,944 shsRDHLRedhill Biopharma$1.96+2.5%$1.92$1.71▼$20.28$4.51M4.22163,693 shs32,813 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+5.59%-17.47%-38.68%-11.88%+60.32%CINGCingulate-4.44%+0.22%+7.62%+8.13%+1,032.83%MRKRMarker Therapeutics-0.63%-1.88%-1.88%+45.37%-71.81%RDHLRedhill Biopharma-12.39%-9.05%+9.14%-7.73%-99.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie1.0605 of 5 stars0.04.00.00.03.60.00.6CINGCingulate3.2889 of 5 stars3.55.00.00.02.61.70.6MRKRMarker Therapeutics4.4872 of 5 stars3.85.00.03.92.70.80.6RDHLRedhill BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 4.00Strong BuyN/AN/ACINGCingulate 3.00Buy$26.00450.85% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.17728.09% UpsideRDHLRedhill Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RDHL, CING, MRKR, and BIVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$25.35 per shareN/ACINGCingulateN/AN/AN/AN/A$2.32 per shareN/AMRKRMarker Therapeutics$6.59M2.73N/AN/A$1.73 per share0.92RDHLRedhill Biopharma$8.04M0.56N/AN/A($3.66) per share-0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$79.10N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)CINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)RDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ALatest RDHL, CING, MRKR, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRKRMarker Therapeutics-$0.55N/AN/AN/A$0.72 millionN/A8/12/2025Q2 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A5/12/2025Q3 2025BIVIBioVie-$3.20-$1.50+$1.70-$0.15N/AN/A5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.319.31CINGCingulate0.161.871.87MRKRMarker TherapeuticsN/A6.796.79RDHLRedhill BiopharmaN/A0.540.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CINGCingulate41.31%MRKRMarker Therapeutics22.39%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%CINGCingulate17.06%MRKRMarker Therapeutics14.50%RDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie101.86 million1.81 millionNo DataCINGCingulate204.25 million3.52 millionNot OptionableMRKRMarker Therapeutics6011.32 million9.67 millionNot OptionableRDHLRedhill Biopharma2102.30 million2.14 millionNo DataRDHL, CING, MRKR, and BIVI HeadlinesRecent News About These CompaniesRedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide studyJuly 2, 2025 | msn.comRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate CancerJuly 1, 2025 | prnewswire.comRedHill Biopharma Ltd. (RDHL) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment WinMay 13, 2025 | prnewswire.comRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology CongressMay 2, 2025 | prnewswire.comRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107April 28, 2025 | prnewswire.comRedHill Biopharma receives non-compliance letter from NasdaqApril 18, 2025 | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 18, 2025 | finanznachrichten.deRedHill Biopharma announces publication in journal on OpaganibApril 17, 2025 | markets.businessinsider.comRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 17, 2025 | prnewswire.comRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market DisruptionApril 16, 2025 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | prnewswire.comRedHill Biopharma to submit UK MAA for TaliciaMarch 18, 2025 | markets.businessinsider.comRedHill to file FDA-approved Talicia for UK marketingMarch 18, 2025 | thepharmaletter.comTRedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing AuthorisationMarch 18, 2025 | finanznachrichten.deRedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing AuthorisationMarch 18, 2025 | prnewswire.comRedHill Biopharma announces plans to advance program for Crohn’s diseaseMarch 13, 2025 | markets.businessinsider.comRedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 ResultsMarch 12, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Datadog Joins S&P 500, Triggering a New Wave of UpsideBy Gabriel Osorio-Mazilli | July 7, 2025View Datadog Joins S&P 500, Triggering a New Wave of UpsideRDHL, CING, MRKR, and BIVI Company DescriptionsBioVie NASDAQ:BIVI$7.31 +0.32 (+4.58%) Closing price 04:00 PM EasternExtended Trading$7.30 -0.01 (-0.21%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Cingulate NASDAQ:CING$4.72 +0.20 (+4.42%) Closing price 04:00 PM EasternExtended Trading$4.60 -0.12 (-2.54%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Marker Therapeutics NASDAQ:MRKR$1.59 +0.02 (+1.27%) Closing price 04:00 PM EasternExtended Trading$1.50 -0.10 (-5.97%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Redhill Biopharma NASDAQ:RDHL$1.96 +0.05 (+2.46%) Closing price 03:50 PM EasternExtended Trading$1.96 0.00 (-0.05%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
